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Background: Understanding the effect of early kangaroo mother care on survival of mild-moderately unsta-
ble neonates <2000 g is a high-priority evidence gap for small and sick newborn care.
Methods: This non-blinded pragmatic randomised clinical trial was conducted at the only teaching hospital in
The Gambia. Eligibility criteria included weight <2000g and age 124 h with exclusion if stable or severely
unstable. Neonates were randomly assigned to receive either standard care, including KMC once stable at
>24 h after admission (control) versus KMC initiated <24 h after admission (intervention). Randomisation
was stratified by weight with twins in the same arm. The primary outcome was all-cause mortality at 28
postnatal days, assessed by intention to treat analysis. Secondary outcomes included: time to death; hypo-
thermia and stability at 24 h; breastfeeding at discharge; infections; weight gain at 28d and admission dura-
tion. The trial was prospectively registered at www.clinicaltrials.gov (NCT03555981).
Findings: Recruitment occurred from 23rd May 2018 to 19th March 2020. Among 1,107 neonates screened
for participation 279 were randomly assigned, 139 (42% male [n = 59]) to standard care and 138 (43% male
[n = 59]) to the intervention with two participants lost to follow up and no withdrawals. The proportion
dying within 28d was 24% (34/139, control) vs. 21% (29/138, intervention) (risk ratio 0¢84, 95% CI 0¢55 
1¢29, p = 0¢423). There were no between-arm differences for secondary outcomes or serious adverse events
(28/139 (20%) for control and 30/139 (22%) for intervention, none related). One-third of intervention neo-
nates reverted to standard care for clinical reasons.
Interpretation: The trial had low power due to halving of baseline neonatal mortality, highlighting the impor-
tance of implementing existing small and sick newborn care interventions. Further mortality effect and
safety data are needed from varying low and middle-income neonatal unit contexts before changing global
guidelines.
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Research in context
Evidence before this study
Kangaroo mother care (KMC) is recommended by the World
Health Organization (WHO) for all stable neonates 2000 g
with the latest Cochrane review (2016) reporting 40% relative
reduction in mortality at discharge or 40  41 weeks’ post-
menstrual age, compared to standard incubator care (RR=0¢60,
95% CI 0¢39  0¢92; 8 trials; 1736 neonates). This Cochrane
review highlighted insufficient evidence to recommend early-
onset continuous KMC before stabilisation, and recommended
methodologically rigorous trials to determine the effectiveness
of KMC in “unstabilised or relatively stabilised low-birth weight
infants”. We searched clinicaltrials.gov and the Australian New
Zealand Clinical Trials Register with the search terms “kanga-
roo”, “kangaroo mother care”, “kangaroo method” or “skin to
skin contact AND neonate”, and identified two other trials cur-
rently ongoing or recently closed which also address this prior-
ity question (OMWaNA; clinicaltrials.gov NCT02811432 and
WHO’s iKMC trial; ACTRN12618001880235).
Added value of this study
This pragmatic, individually randomised controlled trial
(n = 279) conducted at a Gambian level 2+ neonatal unit did not
find evidence of improved survival at 28 postnatal days with
early KMC versus standard care for mild-moderately unstable
neonates <2000 g. Halving of inpatient case-fatality rates (48%
pre-trial vs. 23% during-trial) contributed to reduced power to
detect a difference in the primary outcome. There was no evi-
dence of between-arm differences for secondary outcomes or
serious adverse events however one-third of intervention neo-
nates reverted to standard care for clinical reasons. Achieving
prolonged KMC duration was challenging with barriers includ-
ing absence of willing KMC providers, provision to twin pairs
and need for a respectful neonatal unit environment.
Implications of all the available evidence
Implementation of early KMC for vulnerable unstable newborns
is challenging, and studies are required in a range of neonatal
care settings before this can be recommended as standard care.
Implementation research is needed from perspectives of the
mother/family, healthcare provider as well as health systems
planning and costings data, with understanding of the KMC
dose-response by risk profile a priority evidence gap. Although
this trial did not show a mortality effect, findings can contribute
to future meta-analyses, and demonstrate potential for sub-
stantial survival gains through improved quality small and sick
newborn care.
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An estimated 15 million neonates are born preterm (<37 weeks
gestation) annually, over 80% in Asia and Sub-Saharan Africa (SSA)
[1]. Complications of preterm birth result in >1 million neonatal
deaths/year [2] with the highest risk of death during the first 24 h
after delivery [3]. Birth weight <2000 g is a proxy for prematurity yet
this group of vulnerable neonates may also include term neonates
who are small for gestational age (SGA) as well as preterm neonates
with or without growth restriction. Mortality risk is greatest for pre-
term neonates who are also SGA [4] and all neonates <2000 g require
high quality small and sick newborn care especially during the first
day after birth. There is an urgent need for evidence-basedinterventions for neonates <2000 g in order to meet the Sustainable
Development Goal 3.2 target of 12 neonatal deaths/1000 live births
by 2030 [5].
Kangaroo mother care (KMC) is recommended as standard care
for all stable neonates 2000 g [6]. KMC is an evidence based package
of care, with key component of prolonged skin-to-skin contact
between neonate and caregiver [6]. This is linked to promotion of
exclusive breastmilk feeding and early hospital discharge [7]. Com-
pared to incubator care, KMC is associated with a 3651% reduction
in mortality at discharge or at 4041 weeks postmenstrual age
[79]. There is a lack of evidence for KMC in “relatively stable or
unstable” neonates [9], hence it is not currently recommended by
WHO for this population [6]. This evidence-gap is a high priority [9]
with several on-going or recently completed trials in SSA and South
Asia [10,11].
If shown to be effective and safe, early KMC may result in a para-
digm shift in hospital care of small and sick neonates, both improving
outcomes and promoting family-centred care. eKMC was intended to
be a pragmatic trial, aiming to assess the effect of early KMC on 28-
day survival of mild-moderately unstable neonates following neona-
tal unit admission. As secondary objectives, we explored potential
ways by which early KMC may alter preterm outcomes such as ther-
mal control [12]; cardio-respiratory stabilisation [13]; promotion of
breastfeeding [14] and avoidance of infections [9]. Secondary objec-
tives also included safety evaluation, for which there is limited data
from low and middle-income countries (LMIC).
2. Methods
2.1. Design & setting
An individually randomised superiority trial was conducted at
Edward Francis Small Teaching Hospital (EFSTH), the only teaching
hospital and referral Neonatal Unit (NNU) in The Gambia. Twelve per-
cent of Gambian neonates are born preterm [1] and 29% of neonatal
deaths at EFSTH are due to complications of prematurity [15] with
48% case fatality for neonates <2000 g [16]. Special newborn care
(WHO Level 2+) [16] was available with oxygen via concentrators,
phototherapy, pulse-oximetry for spot-checks, intravenous (IV) fluids
via burettes and gastric tube feeding. Bubble CPAP (bCPAP) was intro-
duced to the NNU in early 2018, but only became embedded in small
and sick newborn care around the time of trial onset. Mechanical
ventilation, surfactant, blood pressure measurement, continuous
pulse oximetry monitoring and parenteral nutrition were unavail-
able. Running water was intermittently available, with water buckets
and soap for maternal hand washing and no access to an autoclave
for sterilisation of re-usable equipment. Two nurses per shift cared
for up-to 80 neonates during peak periods. Continuous KMC was
established as standard of care for stable neonates 2000 g in Sep-
tember 2017, provided on an eight-bed KMC unit adjacent to the
NNU. An area within the NNUwas identified as the “trial area”, where
both control and intervention arm participants were managed.
2.2. Participants, screening & consent
All admitted singleton or twin neonates weighing <2000 g and
aged 124 h were screened for exclusion criteria, including: recruit-
ment to another research study; triplets; major congenital malforma-
tions; severe jaundice; seizures; stable or severely unstable; absence
of study bed and lack of written informed consent within 24 h of
admission (Fig.S1). Presence of mother or another caregiver who was
willing to provide the intervention was also required. Our target pop-
ulation was mild-moderately unstable neonates with severely unsta-
ble newborns excluded due to the operational challenges of
providing KMC alongside resuscitation and bCPAP in our setting [17].
Stable neonates were excluded as they should already receive KMC.
Fig. 1. Definitions of stability used in eKMC trial. Originally published by BMC [18]. a. Criteria for starting bCPAP were: Silverman-Anderson score 4 with no apnoea and/or heart
rate <100 bpm. b. SPO2, respiratory rate and heart rate were recorded every minute for a 10 min period and classified according to most frequent category of observations present
for >5 min. c. Upper limit of SPO2 for providing oxygen therapy was 95%. Abbreviations: bCPAP= Bubble continuous positive airway pressure; RR=Respiratory rate; h=hours;
HR=Heart rate; SPO2=oxygen saturation.
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care settings [18], we developed pragmatic stability definitions based
on clinical and cardio-respiratory observations feasible for low-
resource settings, namely respiratory rate, heart rate, oxygen satura-
tion and work of breathing (Fig. 1). Thresholds for abnormality were
chosen for consistency with WHO recommended references ranges
[19], with a lower oxygen saturation threshold (<88%) to avoid over
classification of severe instability. Cardio-respiratory stability was
assessed in potentially eligible neonates over 10 min with a NoninTM
2500A pulse oximeter. Mildly unstable neonates were immediately
recruited. Moderately and severely unstable neonates underwent
repeat assessment after 3 h with exclusion of severely unstableneonates at this stage. Written informed consent was sought from
the first caregiver on-site within 24 h of admission. The parent was
preferred consenter but other relatives could consent with later
parental assent/consent to continue participation. If consent was pro-
vided at >3 h since the last stability assessment, stability status was
re-checked to avoid recruitment of neonates out-with the stability
definition.
2.3. Randomisation, allocation and blinding
The unit of randomisation was the mother with stratification by
the neonate’s admission weight (<1200 g/ 1200 g; cut-off chosen to
4 H. Brotherton et al. / EClinicalMedicine 39 (2021) 101050identify highest risk neonates). If both babies in a twin set were eligi-
ble, they were randomised to the same arm for convenience of care,
according to the first eligible twins’weight. Random permuted blocks
of varying size were used and randomisation sequence was computer
generated by an independent statistician. Selection bias was avoided
by using sequentially numbered, opaque sealed envelopes, opened
by research nurse after baseline assessment and time-stamped to
identify any subversion of sequence. Due to the nature of the inter-
vention, blinding of intervention procedures and outcome assess-
ments wasn’t possible but laboratory processes (for confirmed
infections) and analyses were blinded to allocation.
2.4. Intervention
We defined KMC as skin-to-skin contact in the kangaroo position,
with the naked (except for hat and diaper) neonate laying prone next
to the caregivers’ chest in a frog-leg position with head turned side-
ways. A cloth wrapper [Thari design] was used to secure the neonate
in KMC position, including straps tied at the sides of the infant to
enable easy access [17]. Research nurses encouraged the KMC pro-
vider to start KMC immediately after allocation and to provide as
close to continuous skin-to-skin contact as possible [6], aiming for
>18 h/day in prolonged sessions. Beds were provided on the NNU for
the exclusive use of the intervention arm caregivers. All other treat-
ments were provided simultaneously with KMC, except for bCPAP
which was provided in the high dependency area of the NNU where
it was not feasible to have adult KMC beds. During breaks to pray,
wash, eat etc., the neonate was placed on a non-servo controlled radi-
ant heater or incubator in the same room. Twins received KMC from
the same or different KMC providers. Clinical criteria for stopping
KMC were pre-specified and included: severe instability, including
need for bCPAP; apnoea needing resuscitation; widespread rash on
neonate or KMC provider; severe abdominal distension; omphalitis;
phototherapy; blood transfusion; seizures, and KMC provider unwill-
ing or unavailable to provide continuous KMC. Criteria for re-starting
KMC were also pre-specified (eFig.1) [17]. Neonates were transferred
to the KMC unit to continue KMC once stability criteria were met and
neonates tolerated enteral feeds without IV fluids for 12 h.
2.5. Control
Control neonates were managed in an incubator or under a radi-
ant heater (non-servo controlled) in the same room as intervention
neonates. The caregiver could touch and feed but KMC was not per-
mitted until the neonate met stability criteria at >24 h after admis-
sion (Fig.1). Intermittent KMC (minimum 60 min skin-to-skin contact
several times a day) was provided whilst the neonate was still on the
neonatal unit, with continuous KMC starting after transfer to the
KMC unit once stability criteria were met and neonates tolerated
enteral feeds without IV fluids for 12 h.
2.6. Outcome measures
The primary outcome was all-cause mortality at 28 days. Second-
ary outcomes included: time to death; stability at 24 h, using the Sta-
bility of Cardio-Respiratory in Preterm Infants (SCRIP) score [20],
modified for relevance to neonates receiving oxygen [17]; prevalence
of hypothermia (axillary temperature <36¢5 °C) at 24 h; proportion
exclusively breastfeeding at discharge; mean daily weight gain at 28
+/5d; incidence of clinically suspected infection from age 3 to 28
days or latest follow-up, and mean duration of admission.
2.7. Trial procedures, including safety assessments
A detailed description of trial procedures is available in the pub-
lished protocol (efig.1) [18].To avoid preferential education of caregivers in the intervention
arm, the first caregiver available on the NNU for both groups was sen-
sitised about NNU policies, KMC provision, hand hygiene and danger
signs.
Continuous pulse-oximetry monitoring was performed for trial
participants during the first 24 h and continued until the neonate
was stable off oxygen. Heart rate, oxygen saturation (SPO2), respira-
tory rate, blood glucose, axillary temperature, stability status, and
adverse events were recorded six-hourly for the first 24 h then daily
whilst on the neonatal unit. Following transfer to the KMC unit, study
assessments were done on postnatal days 7, 14, 21, 28, with daily
vital sign checks by EFSTH team as per standard care. Weight was
measured daily from postnatal day five and length/head circumfer-
ence weekly. A clinician examined participants within 24 h of enrol-
ment and evaluated gestational age with the New Ballard score
within 48 h [21].
The WHO’s Possible Serious Bacterial Infection (PSBI) criteria were
used to identify clinical deterioration with adaptations to increase
relevance for hospitalised preterm infants by including excessive gas-
tric aspirates, need for oxygen or bCPAP and breathing rate >80 bpm
(efig.1) [17]. If 1 aPSBI criteria was present, neonates were assessed
by a clinician for infection, which was diagnosed as per a validated
nosocomial risk score for preterm neonates (age >72 h with 1 of
apnoea, lethargy, pallor, jaundice, or hepatomegaly) [22]. Peripheral
blood and CSF (if no contra-indication present) samples for culture
were obtained under aseptic technique by trained clinicians if infec-
tion criteria were met (efig.1). Confirmed infection was diagnosed if
suspected infection criteria were present and a known neonatal path-
ogen was isolated. Coagulase negative staphylococcus and bacillus
species were pre-defined as non-pathogenic in this population due to
the absence of indwelling catheters and lines.
Research nurses directly observed and recorded duration spent in
kangaroo position for both arms, documenting timing of each KMC
session, KMC provider and reason for coming out of KMC position. All
other treatments were provided by EFSTH personnel according to
standardised guidelines consistent with standard care and WHO rec-
ommendations for small and sick newborn care [6,19], with compli-
ance monitored daily by trained clinicians to avoid performance bias.
Guidelines included hospital discharge criteria: minimum weight
1.1 kg; >10 g/kg/day weight gain for 3 consecutive days without gas-
tric tube feeding; both twins met weight criteria; stable vital signs
and no health worker concerns; mother willing to continue KMC at
home and able to attend follow-up [17]. The final study visit at post-
natal age 28+/5d was by inpatient review if admitted or scheduled
follow-up at the site with re-imbursement of travel expenses and
home visits for participants who did not attend.
All data were collected by Good Clinical Practice (ICH-GCP)
trained personnel with three to six monthly re-training on study spe-
cific procedures. The REDCapTM electronic data entry system was
used with built-in consistency checks. Double-blind standardisation
assessments for gestational age and anthropometric measurements
were performed to reduce inter-observer variability. Triplicate meas-
urements of temperature and anthropometric data were obtained
and cardio-respiratory parameters were measured over ten minutes
to generate mean values. Calibrated equipment was used for all
measurements including Seca 757 digital weighing scale (2 g grada-
tion) and glucometers for bedside blood glucose monitoring.
2.8. Microbiological procedures
Blood cultures were processed within 24 h in a BACTEC 9050 BD
at the MRC Unit The Gambia at LSHTM (MRCG) laboratory (ISO15189
accredited) with sub-culture by conventional methods including spe-
cies identification using the API-20 system and antibiotic susceptibil-
ity testing by disc diffusion according to the Clinical and Laboratory
Standards Institute (CLSI) 2018 guidelines.
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A sample size of 392 neonates (196 per arm) was chosen to pro-
vide 80% power to detect a 30% relative difference (48% vs. 34%) in
mortality with a type I error rate of 5%. The baseline mortality rate of
48% was estimated from feasibility study data (56%, 14/25, in-patient
case fatality rate for neonates meeting trial definitions of mild-mod-
erate instability) assuming a 15% relative reduction related to trial
implementation and was consistent with published pre-trial data
[15].
Analyses were done using STATAv.16 with an intention-to-treat
approach, using techniques to account for twin clustering. Between-
arm differences in categorical outcomes were analysed using a gener-
alised estimating equation (GEE) model with log link and an indepen-
dent working correlation structure. A random effects model was used
for continuous outcomes. Cox regression with frailty was used for
time to death with right censoring of data for participants not fol-
lowed up. The primary analysis was unadjusted for covariates with
pre-planned analyses adjusting for twin status, weight, and gesta-
tional age. A pre-planned sub-group analysis of all outcomes was per-
formed for weight and twin pregnancy status with an interaction
term to assess for heterogeneity of treatment effects across sub-
groups. All tests were two-sided and reported without adjustment
for multiple testing. Missing data was low (<5%), hence complete
case analysis was used.
An unblinded interim analysis was conducted by the data safety
monitoring board (DSMB) after randomisation of 50% of the target
sample size (n = 196). In March 2020 the Trial Steering Committee
recommended stopping recruitment early (~70% of target sample
size recruited) as the trial was recognised to now be underpowered
due to reductions in baseline mortality and the COVID-19 pandemic
posed an immediate risk to staff health.Fig. 2. Overview of enrolment, randomisation & inclusion in intention to treat analysis of
scales (6); planned team retraining (5); seizures (3); political protests leading to temporary h
intervention arm were clinical deterioration between screening and start of intervention
h=hours; KMC = Kangaroo mother care.2.10. Ethics
Approval was received from the institutional review board at
LSHTM and the Gambian Government / MRCG Joint Ethics Commit-
tee. This article was prepared in accordance with CONSORT guide-
lines (Online-only material 1) [23].
2.11. Role of the funding source
The funder played no role in study design, data collection, analysis
or interpretation of data, manuscript writing nor decision to submit
for publication.
3. Results
Recruitment spanned from 23rd May 2018 to 19th March 2020
with follow-up completed by 20th April 2020. 1107 newborns were
screened and 279 (25%) met eligibility criteria; 141 were allocated to
receive standard care and 138 to early KMC. Among the main reasons
for non-recruitment were severe instability or death during the
screening process (217/1107, 19.6%), unavailability of a willing KMC
provider during the first 24 h of NNU admission (168/1107, 15.2%)
and limited availability of trial beds on the NNU (77/1107, 7%). There
were no withdrawals and only two neonates were lost to follow-up.
277 neonates were included in the analysis of the primary outcome
(Fig.2).
Our cohort consisted of mostly premature neonates (median ges-
tational age 32 weeks in control, 33 weeks in intervention), with
median admission weight <1.5 kg in both arms (1436 g control;
1459 g intervention) (Table 1). Nearly one-third (32% control vs 30%
intervention) of participants were part of a twin pregnancy and 17%
(both arms) of the cohort were twins with both enroled. Mostprimary outcome. a. Other reasons for non-recruitment were weight 2000 g on trial
alt to recruitment (1) and not known (1). b. Reasons for not receiving early KMC in the
procedures (2); no study bed available (1); no caregiver available (1). Abbreviations:
Table 1
Baseline characteristics of the intention-to-treat population.
Standard care (N = 141) early KMC (N = 138)
Neonatal & perinatal characteristics
Male sex, No (%) 59 (42) 59 (43)
Age at admission (h), median (IQR) 2¢3 (0¢7  5) 2¢3 (0¢9  4¢7)
Age at start of intervention/controla (h), median (IQR) 12¢8 (7¢9  19¢1) 13¢6 (8¢9  19)
Admission weight (g), median (IQR) 1436 (1180 - 1660) 1459 (1204  1650)
Distribution of admission weight,b No (%)
<1200 g 39 (28) 34 (25)
1200 g 102 (72) 104 (75)
Part of twin gestation pregnancy, No (%) 45 (32) 41 (30)
Part of twin pregnancy, both enroled, No (%) 24 (17) 24 (17)
Gestational age (weeks), median (IQR) (n = 271) 32 (31 - 34) 33 (31 - 34)
Distribution of gestational age, No (%)
<28 weeks 4/135 (3) 3/136 (2)
28  31+6 weeks 36/135 (27) 41/136 (30)
32  36+6 weeks 83/135 (61) 81/136 (60)
37 weeks 12/135 (9) 11/136 (8)
Referral-site (EFSTH), No (%) 66 (47) 66 (48)
Health facility delivery, No (%) 121 (86) 126 (91)
Caesarean-section delivery, No (%) 27 (19) 31 (22)
Resuscitation at delivery,c No (%) 10/140 (7) 5 (4)
Perinatal septic risk factors,d No (%) 49/139 (35) 40/137 (29)
Neonatal stability &management at start of intervention/control procedures
Stability status,e No (%)
Stablef 5 (4) 14 (10)
Mildly unstable 86 (61) 73 (53)
Moderately unstable 44 (31) 44 (32)
Severely unstablef 5 (4) 2 (1)
Axillary temperature ( °C), median (IQR)(n = 277) 36¢6 (36¢1  37¢2) 36¢6 (36¢1  37¢1)
Blood glucose (mmol/L), median (IQR)(n = 275) 4¢1 (3¢5  5¢1) 3¢8 (3¢2  4¢9)
Oxygen saturation (SPO2), median (IQR)(n = 274) 97 (96 - 98) 97 (95 - 98)
Oxygen, No (%) 125 (89) 123 (89)
Bubble CPAP, No (%) 5 (4) 2 (1)
IV antibiotics,g No (%) 123 (87) 124/137 (91)
IV maintenance fluids, No (%) 125 (89) 115 (83)
IV vitamin K prophylaxis, No (%) 117 (83) 111 (80)
Apnoea of prematurity prophylaxis (IV caffeine or aminophylline), No (%) 74 (52) 57(41)
a. The start of intervention/control procedures was defined as when a trial pulse oximeter was attached to the neonate, immedi-
ately after allocation yet prior to any intervention procedures commencing.
b. Categories of admission weights as per weight cut offs used for stratification during randomisation.
c. Resuscitation at delivery with one or more of: oxygen, bag-valve-mask ventilation or chest compressions.
d. Perinatal septic risk factors included: maternal fever; maternal chorioamnionitis; offensive smelling liquor; prolonged rupture
of membranes >18 h.
e. Stability definitions as per published protocol18 and as shown in Fig. 1.
f. Stable and severely unstable neonates were excluded during the screening phase but some eligible neonates improved or dete-
riorated during the consent and recruitment process, hence were stable or severely unstable when re-assessed at the start of
intervention/control procedures.
g. Blood cultures were not obtained prior to antibiotic administration as they were not routinely available as part of standard care
at the trial site.
Abbreviations: CPAP = Continuous positive airway pressure; EFSTH= Edward Francis Small Teaching Hospital; g=grams; h = hours;
IQR = Interquartile range; IV = Intravenous; SD = standard deviation; SPO2 = oxygen saturation.
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vs. 91%) and intravenous fluids (89% vs. 83%) before allocation. 92%
(control) vs. 88% (intervention) were mild or moderately unstable at
the start of intervention/control procedures, with the remainder
either improving or deteriorating between the end of screening and
start of study procedures. There were two clinically relevant imbalan-
ces between treatment arms: (1) More neonates in the intervention
arm were stable at the start of intervention/control procedures (2)
Fewer neonates in the intervention arm received apnoea of prematu-
rity prophylaxis before allocation. Baseline characteristics were oth-
erwise balanced between arms (Table 1, eTable 1).
There was no evidence of a difference in mortality between arms
in the primary intention-to-treat analysis, with 34/139 (24%) deaths
in the control group versus 29/138 (21%) deaths in the intervention
group (RR=0¢84, 95% CI 0¢55  1¢29, Table 2) or with the survival
analysis (Fig.3). Adjustment for admission weight, gestational age
and twin status yielded similar results (RR=0¢93, 95% CI 0¢63  1¢36,
eTable 2). A sensitivity analysis excluding neonates not meeting eligi-
bility criteria at the start of intervention/control procedures showedno evidence of between-arm effect difference (28/129 in control vs.
28/124 in intervention. RR=1¢04, 95% CI 0¢65  1¢65, eTable 3).
There was no evidence of between-arm differences in secondary
outcomes, including clinically suspected infections which were rela-
tively common (15% (21/141) of control arm versus 20% (28/138) of
intervention arm. RR=1¢36, 95% CI 0¢81  2¢28) and blood culture
confirmed infections (RR=1¢53, 95% CI 0¢65 3¢64, Table 2). The ten
confirmed infections were all due to gram-negative bacteria with
82% (9/11) of isolates resistant to both 3rd generation cephalosporins
and gentamicin (eTable 4).
Pre-planned sub-group analyses found no evidence of between-
arm differences in outcomes except for admission weight. Among
neonates <1200 g, early KMC was associated with a reduction in
hypothermia at 24 h (RR=0¢55, 95% CI 0¢33  0¢91) with no associa-
tion apparent in neonates 1200 g (RR= 1¢29, 95% CI 0¢87  1¢91; test
of interaction p = 0¢008) (Table 3).
21% (58/279) of participants experienced at least one clinically
relevant non-fatal serious adverse event (SAE), most commonly a life
threatening condition or a condition with high risk of disability
Table 2
Effect of early KMC on primary and secondary outcomes.
Standard care Early KMC Effect estimate (95% CI) P value
All-cause mortality at 28 days, No(%) 34/139 (24) 29/138 (21) RR= 0.84
(0¢55  1¢29)
0¢423











aSCRIP score at 24 h of enrolment, median, (IQR) N = 135 N = 134 MD 0¢05
(0¢25  0¢16)
0¢667
5 (4  6) 5 (4  5)
Hypothermia (T<36¢5 °C) at 24 h of enrolment, No (%) 55/135 (40) 51/134 (38) RR= 0¢93
(0¢69  1¢26)
0¢654
Exclusive breastfeedinga at discharge, No (%) 105/107 (98) 107/109 (98) RR= 1.0
(0¢96  1¢04)
0¢985
Clinically suspected infection from 3  28 days, No (%)b 21/141 (15) 28/138 (20) RR= 1¢36
(0¢81  2¢28)
0¢240
Blood culture confirmed infectionc,d from 3  28 days, No (%) 4/141 (3) 6/138 (4) RR= 1¢53
(0¢65 3¢64)
0¢333
Duration of admission (days), mean (SD) N = 106 N = 108 MD +0.3
(60¢5  75¢1)
0¢833
16¢3 (10¢0) 16¢6 (11¢1)
Weight gain at 28d (g/day), mean (SD) N = 101 N = 103 MD 2¢2
(5¢28  0¢81)
0¢150
12¢5 (12¢1) 10¢3 (10¢1)
Exclusively breastfeeding defined as only receiving breastmilk and no formula milk supplementation.
Defined as neonates with at least 1 suspected infection, as per protocol definition.18 Two neonates (one in each allocation arm) each had
two discrete infection episodes.
Blood cultures were obtained from 92% (47/51) of suspected late-onset infection episodes; 95% (21/22) from control arm and 90% (26/29)
from intervention arm. 21% (10/47) of blood cultures were positive with 6% (3/47) presumed contaminated samples (coagulase negative
staphylococcus isolated) and no between-arm difference in mean blood volume sampled (1.1 ml (SD 0.3) in control arm versus 1.0 ml (SD
0.3) in intervention arm, p = 0.238, student t-test).
CSF samples were obtained from 19 neonates meeting infection criteria and all were negative after 48 h culture.
Abbreviations: CI = confidence intervals; h = hours; HR = Hazard ratio; IQR = Interquartile range; KMC = kangaroo mother care; MD = mean/
median difference in intervention arm; RR= risk ratio; SD = standard deviation.
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with no between-arm differences. One third (46/138) of participants
receiving early KMC met criteria to stop, at a median of 3¢7d (IQR 1¢6
 6¢2d), most commonly due to severe instability (16/46, 35%),Fig. 3. Cumulative incidence of survival over timeisolated apnoea needing resuscitation (10/46, 22%) or needing photo-
therapy (8/46, 17%) (Table 4).
99% (136/138) of neonates in the intervention arm received KMC
with 86% (119/138) starting KMC within 24 h of admission (medianfrom start of intervention/control procedures.
Table 3
Sub-group analysis of eKMC trial outcomes, by admission weight and twin status.
Subgroup No / Total No (%) Effect size (95% CI); P for effect
of intervention within each
sub-group stratum




Standard care (n = 139) Early KMC
(n = 138)
All-cause mortality at
28 days, No (%)
Admission weight <1200 g 19/37 (51) 14/31 (45) RR 0¢88
(0¢53  1¢45); 0¢614
0¢849
Admission weight 1200 g 15/102 (15) 15/107 (14) RR 0¢95
(0¢49  1¢85); 0¢888
Singleton 25/94 (27) 21/97 (22) RR 0¢98
(0¢42  2¢29); 0¢955
0¢721
Twin pregnancy 9/45 (20) 8/41 (20) RR 0¢81
(0¢49  1¢35); 0¢426
Time to death, (h), median Admission weight <1200 g
(n = 19; n = 14)
95 82 HR: 0¢86
(0¢43  1¢71); 0¢665
0¢888
Admission weight 1200 g
(n = 15; n = 15)
107 151 HR: 0¢92
(0¢45  1¢89); 0¢825
Singleton
(n = 25; n = 21)
71 109 HR: 0¢75
(0¢42  1¢34); 0¢334
0¢593
Twin pregnancy
(N = 9; n = 8)
123 76 HR 1.02
(0.39  2.64); 0.970
aSCRIP score at 24 h, mean Admission weight <1200 g
(n = 36; n = 28)
4¢6 4¢6 MD 0
(0¢36  0¢48); 0¢780
0¢490
Admission weight 1200 g
(n = 99; n = 106)
5¢1 5¢0 MD 0¢1
(0¢34  0¢12); 0¢358
Singleton
(n = 90; n = 94)
4¢9 4¢9 MD 0
(0¢24  0¢25); 0¢970
0¢509
Twin pregnancy
(n = 45; n = 40)
5¢0 4¢9 MD 0¢1
(0¢51  0¢22); 0¢440
Hypothermia (T<36¢5 °C)
at 24 h, No (%)
Admission weight <1200 g 25/36 (691) 11/28 (39) RR 0¢54
(0¢33  0¢90); 0¢018
0¢008
Admission weight 1200 g 29/99 (29) 40/106 (38) RR 1¢29
(0¢87  1¢91); 0¢206
Singleton 41/90 (46) 30/94 (32) RR 0¢70
(0¢48  1¢02); 0¢061
0¢008
Twin pregnancy 14/45 (31) 21/40 (53) RR 1¢69
(1¢0  2¢86); 0¢051
Exclusive breast feedinga
at discharge, No (%)
Admission weight <1200 g 18/18 (100) 17/17 (100) RR 1¢0
(0¢96  1¢05); 0¢.973 NA
Admission weight 1200 g 87/89 (98) 90/92 (98) RR 1¢0
(0¢96  1¢05); 0¢973
Singleton 71/71 (100) 75/76 (99) RR 1¢0
(0¢931¢13); 0¢605
NA
Twin pregnancy 34/36 (94) 32/33 (97) RR 1¢0
(0¢93  1¢13); 0¢605
Clinically suspected infection
from 3  28 days, No (%)
Admission weight <1200 g 9/37 (24) 10/31 (32) RR 1¢33
(0¢62  2¢85); 0¢470
0¢856
Admission weight 1200 g 12/104 (12) 18/107 (17) RR 1¢46
(0¢74  2¢88); 0¢277
Singleton 16/96 (17) 22/97 (23) RR 1¢36
(0¢76  2¢43); 0¢298
0¢959
Twin pregnancy 5/45 (11) 6/41 (15) RR 1¢32
(0¢43  4¢0); 0¢627
Blood culture confirmed
infection from 3  28 days, No (%)
Admission weight <1200 g 0/37 (0) 1/31 (3) RR 1¢21
(0¢33  4¢41); 0¢767
NA
Admission weight 1200 g 4/104 (4) 5/107 (5) RR 1¢21
(0¢33  4¢41); 0¢767
Singleton 2/96 (2) 3/97 (3) RR 1¢48
(0¢25  8¢71); 0¢662
0¢935
Twin pregnancy 2/45 (4) 3/41 (7) RR 1¢65
(0¢29  9¢39); 0¢575
Duration of admission (h), mean Admission weight <1200 g
(n = 17; n = 17)
705¢5 677¢4 MD 28¢1
(174¢5  118¢4); 0¢707
0¢595
Admission weight 1200 g
(n = 89; n = 91)
332¢0 347¢3 MD 15¢2
(48¢4  78¢9); 0¢639
Singleton
(n = 70; n = 75)
410¢8 404¢1 MD 6¢7
(88¢9  75¢5); 0¢873
0¢591
Twin pregnancy
(n = 36; n = 33)
355¢2 388¢2 MD 33¢0
(86¢2  152¢2); 0¢588
Weight gain at 28+/5d (g/day), mean Admission weight <1200 g
(n = 17; n = 16)
6¢1 6¢9 MD 0¢8
(6¢64  8¢19); 0¢837
0¢369
Admission weight 1200 g
(n = 83; n = 88)
13¢9 10¢9 MD 2¢9
(6¢19  0¢33); 0¢078
Singleton
(n = 65; n = 72)
12¢9 11¢2 MD 1¢7
(5¢38  2¢03); 0¢377
0¢548
Twin pregnancy
(n = 35; n = 32)
11¢9 8¢2 MD 3¢7
(8¢95  1¢64); 0¢177
Exclusively breastfeeding defined as only receiving breastmilk and no formula milk supplementation.
Abbreviations: CI = confidence intervals; h = hours; HR = Hazard ratio; IQR = Interquartile range; KMC = kangaroo mother care; MD = mean difference in intervention
arm; NA = Not available; RR= risk ratio; SD = standard deviation.
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Table 4
Provision of KMC to both trial arms, with measures of intervention adherence.
Standard care (N = 141) Early KMC (N = 138)
Received KMC at any time during admission, No (%) 109 (77) 136 (99)
Age at starting KMC (h), median (IQR) 104¢5 (73¢4 – 166¢1) 15¢2 (10¢7 – 22¢0)
Started KMC within 24 h of admission, No (%) 0 (0) 119 (86)
Time from admission to first KMC (h), median (IQR) 101¢1 (71.¢8 – 165¢1) 12 (7¢4 – 17¢9)
First person to provide KMC, No (%)
Mother 98/109 (90) 73/136 (54)
Aunt 5/109 (5) 33/136 (24)
Grandmother 6/109 (6) 24/136 (18)
Other 0/109 (0) 6/136 (4)
Day 1: Duration in KMC position (h), median (IQR) 0 (0 – 0) 8.9 (5¢4 – 11¢7)
Day 2: Duration in KMC position (h), median (IQR) 0 (0 – 0) 7¢4 (4¢2 – 10¢6)
Day 3: Duration in KMC position (h), median (IQR) 0 (0 – 0¢1) 7¢3 (2¢6 – 10¢5)
Day 4: Duration in KMC position (h), median (IQR) 0 (0 – 1¢1) 6¢8 (3¢0 – 10¢0)
Day 5: Duration in KMC position (h), median (IQR) 0 (0 – 3¢0) 6¢8 (1¢8 – 9¢5)
Day 6: Duration in KMC position (h), median (IQR) 0¢7 (0 – 3¢5) 5¢8 (1¢4 – 9¢6)
Day 7: Duration in KMC position (h), median (IQR) 1¢8 (0 – 6¢0) 4¢0 (0 – 9¢2)
Total duration in KMC position (h), median (IQR) 21¢6 (1¢4 – 63¢8) 66¢8 (33¢9 – 125¢5)
Duration in KMC/day of enrolment (h), median (IQR)a 2¢1 (0¢2 – 3¢7) 6¢7 (4¢3 – 8¢5)
Days that ≥1 h of KMC provided, median (IQR) 5 (1 – 10) 9.5 (5 – 16)
Proportion discontinuing intervention, No (%) NA 46 (33¢3)
Reason for discontinuation of intervention, No (%)
Severely unstableb NA 16/46 (35)
Isolated apnoea needing resuscitation NA 10/46 (22)
Severe jaundice NA 8/46 (17)
Recurrent hypoglycaemia NA 2/46 (4)
Severe abdominal distension NA 2/46 (4)
Otherc NA 8/46 (17)
Age at stopping intervention (days), median (IQR) NA 3¢7 (1¢6 – 6¢2)
Proportion re-starting KMC once stability criteria met 22/46 (48)
a. 11% (15/138) of the intervention arm and 0.7% (1/141) of the control arm spent >10 h/d in KMC position
from enrolment to discharge or last study visit if admitted beyond 28d of age.
a. Severe instability defined as per protocol criteria18 and in Fig. 1.
b. Other reasons for discontinuation of the intervention were: seizures; omphalitis; neonatal skin infection;
maternal skin infection; blood transfusion; non-severe presentation of infection; aspiration of milk; died
(n = 1 each).
Abbreviations: CI = confidence intervals; h = hours; IQR = Interquartile range; KMC = kangaroo mother care;
NA = Not available.
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(median 8¢9 h/day), reducing to between 4  7.4 h/day from day two
(Table 4). Over three-quarters (77%, 109/141) of control participants
received KMC during admission, none within the first 24 h and
median 4¢4 days old at initiation (Table 4, eFig.2).
There was no evidence of differences in the proportions of partici-
pants receiving concomitant oxygen (97% in control vs. 95% in inter-
vention), bCPAP (13% vs. 14%), ampicillin and gentamicin (99% in
both arms), gastric tube feeding (86% vs. 91%) and apnoea of prema-
turity prophylaxis (82% vs. 75%) during hospital stay. However, con-
trol participants received more meropenem (4 vs 0; p = 0¢046) and
less cefuroxime than intervention participants (0 vs 5; p = 0¢023)
(eTable 6).
4. Discussion
This randomised trial in a Gambian level 2+ neonatal unit did not
provide evidence that early KMC for mild-moderately unstable neo-
nates results in a mortality reduction compared with standard care. A
halving of in-patient case-fatality rates (CFR) (48% pre-trial [15] vs.
23% during the trial) contributed to reduced power (~30%) to detect a
30% between-arm difference and the target sample size was not
achieved. The median duration spent in KMC position for interven-
tion participants was 6.7 h/day, reflecting known challenges in
achieving prolonged KMC duration [24] and possibly contributing to
the lack of effect. Secondary outcomes showed no between-arm dif-
ferences, except for reduced hypothermia in neonates <1200 g.
The halving of baseline CFR in our cohort was likely influenced by
both improvements to small and sick newborn care during the trial
preparation phase (e.g. KMC implementation for stable newborns,increasing use of bCPAP) and enhanced clinical monitoring necessary
for ethical trial conduct [25], protocol compliance and avoidance of
performance bias.
Despite caregiver education and efforts to promote compliance,
intervention neonates spent less than the recommended 18 h/day6 in
the kangaroo position, with median 6.7 h/day. The minimum thresh-
old of KMC exposure for a mortality reduction to be achieved is not
known [6,9] and mortality reductions are reported with >20 h/day
[9] and >22 h/day [8]. The iKMC trial reported an increased risk of
death for neonates receiving <10 h/day of skin-to-skin contact, but
this may have been confounded by medical issues precluding longer
durations [26]. Despite known benefits, 18 h/day KMC for stable
neonates is often not achieved [24,27]. Promoting early KMC for
unstable neonates for prolonged periods is even more challenging
[28]. The longest duration spent in KMC position for our intervention
neonates was during the first 24 h of trial participation (median
8.9 h/day), when neonates were still receiving oxygen, IV fluids and
undergoing 6-hrly trial assessments. There-after, the daily duration
reduced to between 4 h/day and 7.4 h/day. The iKMC trial achieved
KMC duration of 16.9 h/day on the neonatal unit, with maternal sup-
port from dedicated study personnel [26]. Providing intensive health
worker support for KMC was not possible within our trial as both
research and hospital personnel had high workloads and multiple
responsibilities with low nurse to patient ratios. KMC sessions were
interrupted for medical procedures, routine neonatal cares (feeding,
including expression of mother’s milk) and for the KMC provider to
rest, eat, pray and bathe. Other challenges to providing prolonged
KMC duration included mothers being absent due to maternal illness,
post-caesarean section or delivery at another health facility. This is
reflected in nearly half of our intervention arm receiving first KMC
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importance of family support for KMC [29]. The high proportion of
twins (17% of our cohort were twins both enroled) may have also
affected provision of prolonged KMC, due to the reticence of KMC
providers to perform KMC with unstable twins simultaneously. The
introduction of adult beds onto the NNU to enable continuous KMC
was an important operational challenge, requiring re-organisation of
patient flow, consideration of the infection prevention control impli-
cations and need to provide a respectful environment.
Our findings are in contrast to those from a small Ethiopian single
centre trial reporting a 40% mortality reduction with KMC at < 24 h
after delivery [30]. Detailed information on screening, randomisation
and baseline stability were not reported, hence we cannot adequately
compare populations and study design. However, a lower proportion
received oxygen (~35% vs 89% in eKMC trial) and IV fluids (55% vs
86% in eKMC trial), suggesting a more stable cohort in the Ethiopian
trial. The iKMC trial recently reported a 25% relative reduction in 28-
day mortality (RR 0.75, 95% CI 0.64 0.89, p = 0.001) with immediate
KMC, started at 1.3 h after birth [27]. This multicentre trial recruited
from five tertiary hospitals in India and Africa and identified statisti-
cally significant 28-day mortality reductions in the sub-groups of
neonates 1.5  1.799 kg, singletons and those recruited at the Indian
site [26]. An important difference with our trial was that iKMC sites
had a higher level and quality of newborn care (WHO level 3), indi-
cated by the lower control arm mortality rate of 15.7% and lower
prevalence of hypothermia (10% vs 3840% in our cohort) [26]. Infor-
mation about the stability status of iKMC participants at baseline is
not provided, hence we cannot make direct comparisons with our
cohort. Another important difference was our inclusion of extremely
low birth weight (<1 kg) neonates, comprising 11% of our cohort and
not represented in the iKMC trial [26]. This may have further reduced
intervention effects in our study due to the high risk of surfactant
deficiency and our inability to simultaneously provide bCPAP and
KMC.
In contrast to evidence that KMC improves stability scores at post-
natal 6 h [8,13], we found no evidence of a difference at 24 h of enrol-
ment. More detailed analyses are planned to compare with existing
evidence that KMC positively regulates respiratory stability [8]. Our
finding that KMC reduces hypothermia in neonates <1200 g is con-
sistent with existing evidence [8,9] and has clinical significance for
this population at greatest risk of hypothermia. Both arms were
admitted for 16 days with no difference between arms. This is similar
to the duration of stay of approximately two weeks reported by
iKMC [26] and likely reflects the lack of effect of early KMC on weight
gain and breastfeeding in our cohort, which were the main criteria
for discharge.
The absence of effect of KMC on infections contrasts with previous
meta-analyses reporting a 65% reduction in nosocomial infection [9]
and 50% reduction in severe infection [8] with KMC in stable new-
borns. However, previous KMC trials used varied clinical infection
definitions [8,9,26] and we are the first to report clear apriori clinical
infection definitions combined with microbiologically confirmed
infections and low-risk of detection bias. We found no evidence that
KMC reduces infections, consistent with three previous studies
reporting culture-confirmed infections which were included in the
most recent Cochrane review [9]. The iKMC trial reported a 18%
reduction in suspected sepsis with immediate KMC (RR 0.82, 95% CI
0.73  0.93) but used a non-validated non-specific clinical definition
without microbiological confirmation. Two of the iKMC sites admit-
ted control and intervention neonates to different NICUs, with newly
built Mother-NICUs for the intervention arm [26]. Thus, the possibil-
ity of varying environmental exposures for nosocomial infections
cannot be excluded and detection bias is also a risk. As for many
LMIC neonatal units, infection prevention is a major challenge at
EFSTH, with recent endemic Burkholderia cepacia and epidemic
multi-drug resistant (MDR) Klebsiella pneumoniae outbreaks withcontaminated intravenous fluids and antibiotics implicated in trans-
mission [30,31]. This is consistent with the predominance of MDR-
gram negative bacteria causing invasive infections in our cohort and,
although we cannot comment on acquisition of invasive isolates, this
warrants further study. It is possible that the effect of KMC on reduc-
ing infection risk may vary depending on the nosocomial context of
the setting. Environmental exposures such as contaminated fluids
and antibiotics are an infection risk regardless of when KMC is started
and strengthening of infection prevention control procedures, includ-
ing promotion of hand hygiene for KMC providers and health work-
ers, should be ensured before KMC implementation and provision.
We cannot fully determine the safety of early KMC due to having
low power for mortality, however we observed that it can be pro-
vided safely if continuous pulse-oximetry monitoring and targeted
caregiver education are also in place. Pulse-oximetry monitoring
should be part of safe oxygen provision for all neonates [6], yet is
inconsistently available in many LMIC settings and was not widely
available at the site prior to trial implementation. We advise caution
to extrapolating our safety findings to settings without continuous
pulse-oximetry monitoring, as one-third of the intervention group
stopped KMC due to clinical deterioration and prompt detection of
life-threatening conditions is essential. We recommend that neo-
nates who are receiving KMC at the same time as oxygen should be
continuously monitored with pulse oximetry.
eKMC is one of the first RCTs addressing the priority question of
the mortality effect of early KMC in unstable neonates. Our results
are generalisable to LMIC level 2/2+ neonatal units providing oxygen
and continuous pulse-oximetry which have a high risk of nosocomial
infection. As per Cochrane recommendations, we report clear defini-
tions of eligibility and stability [9] and used a clinical infection defini-
tion based on a validated clinical score for preterm neonates [22] as
well as reporting blood culture confirmed infections. We achieved
high levels of protocol compliance for timing of KMC initiation, with
a large between-group gap, but did not achieve targets of >18 h/day.
KMC trials have some inherent limitations such as the inability to
blind the intervention. Despite meticulous screening and allocation
methods, there were minor differences in baseline stability between
arms but these are probably due to chance and are not likely to have
affected our results, as shown by the sensitivity analysis. We mini-
mised performance bias by managing both arms in the same environ-
ment, implementing a standardised guideline and ensuring
comparable between-group education. We had limitations in our
data collection methods for KMC duration due to small size of our
research team and possible under-estimation of KMC delivered due
to high work-load and competing responsibilities. Accurate and vali-
dated methods of measuring KMC duration is a research gap with rel-
evance for both routine health management information systems
[24] and other KMC trials.
Due to improvements in survival and cessation of the trial before
achieving the intended sample size, our trial had low power for the
primary outcome but was adequately powered for some secondary
outcomes. Our results may contribute to future meta-analyses and
give safety and implementation insights into early KMC use in unsta-
ble neonates. Our methods and outcomes are purposefully similar to
other, larger trials in LMIC [10].
More data about effectiveness and safety of early KMC is needed
from settings with similar contexts of care. Understanding the mini-
mum KMC duration needed for mortality effect is a key gap. Further
research into infection prevention effects of KMC is needed with
standardised definitions, microbiological and genomic analysis,
including effects on neonatal microbiome and MDR-gram negative
bacteria carriage. Implementation of KMC for any stability level is
challenging and we urgently need more insights into how to promote
prolonged KMC for stable and unstable neonates from health sys-
tems, health worker and mother/family perspectives, including eco-
nomic evaluations.
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highlights the substantial survival gains possible with higher quality
implementation of currently recommended small and sick newborn
care. Due to low power, we cannot draw definitive conclusions about
the mortality effects of early KMC in unstable neonates. However,
our results may contribute to meta-analyses and provide important
safety and implementation insights into the use of early KMC in
unstable neonates on level 2/2+ special care neonatal units. Larger tri-
als from similar settings are needed before policy and programmatic
change can be recommended.
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